The Parties recognise that pharmaceutical products [As defined in Annex 2-D (Pharmaceutical Products and Medical Devices).] and plant protection products [Plant protection products, in the form in which they are supplied to the user, consist of or contain active substances, safeners or synergists, and are intended for one of the following uses: (a) protecting plants or plant products against all harmful organisms or preventing the action of such organisms, unless the main purpose of these products is considered to be for reasons of hygiene rather than for the protection of plants or plant products; (b) influencing the life processes of plants, such as substances influencing their growth, other than as a nutrient; (c) preserving plant products, in so far as such substances or products are not subject to the European Union’s special provisions on preservatives; (d) destroying undesired plants or parts of plants, except algae unless the products are applied on soil or water to protect plants; or (e) checking or preventing undesired growth of plants, except algae unless the products are applied on soil or water to protect plants.] protected by a patent in their respective territories are subject to an administrative authorisation or registration procedure before being put on their markets.
The Parties shall provide, at the request of the patent owner, for the extension of the duration of the rights conferred by the patent protection to compensate the patent owner for the reduction in the effective patent life as a result of the first authorisation to place the product on their respective markets. The extension of the duration of the rights conferred by the patent protection may not exceed five years [This is without prejudice to a possible extension for paediatric use, if provided for by the Parties.].